Rate My Professor Chris Chiu

Chiu's research specializations encompass B and T cell immunity to recurrent viral infections, including respiratory syncytial virus (RSV), influenza, and herpesviruses, with an emphasis on developing superior vaccines. He leads a research group that utilizes controlled human infection challenge models to investigate systemic and mucosal immune responses against influenza and RSV, elucidating correlates of protection and mechanisms underlying disease severity. He spearheaded the first-in-the-world SARS-CoV-2 human challenge study during the COVID-19 pandemic, producing essential data on infection dynamics, diagnostics, and transmission that shaped national infection control policies. As Director of the Imperial Network for Vaccine Research (INVaR), Chiu promotes collaborative clinical vaccine trials, public engagement, and efforts to address vaccine hesitancy. He chairs international consortia advancing human challenge studies for pandemic preparedness, integrating fundamental research with policy and industry collaboration. Chiu's contributions have earned him election as a Fellow of the Academy of Medical Sciences in 2025, in addition to his prior Wellcome Trust and MRC fellowships.